Summary Table:
GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)

Summary Figure:
GLOBAL MARKETS FOR PRESCRIPTION DRUGS TO TREAT ENDOCRINE AND METABOLIC DISEASES COVERED IN THIS REPORT, THROUGH 2011 ($ MILLIONS)

Table 1 HYPOTHALAMIC NEUROHORMONES

Table 2 EFFECTS OF ANTIHYPERTENSIVE AGENTS ON SELECTED CORONARY RISK FACTORS

Table 3 CLASSIFICATION OF BLOOD PRESSURE FOR ADULTS AGE 18 YEARS AND OLDER

Table 4 CLASSIFICATION OF CHRONIC ANOVULATION

Table 5 LABORATORY EVALUATION OF THYROID DISORDERS

Table 6 CLASSIFICATION OF HYPERTHYROIDISM

Table 7 BODY MASS INDEX RATIOS AND CLASSIFICATION OF OBESITY

Table 8 SELECTED ADRENERGIC INHIBITORS: PRECAUTIONS AND SIDE EFFECTS

Table 9 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, THROUGH 2011 ($ MILLIONS)

Figure 1 GLOBAL MARKET FOR ADRENERGIC INHIBITORS, 2004-2011 ($ MILLIONS)

Table 10 SELECTED ACE INHIBITORS: PRECAUTIONS AND SIDE EFFECTS

Table 11 GLOBAL MARKET FOR ACE INHIBITORS, THROUGH 2011 ($ MILLIONS)

Figure 2 GLOBAL MARKET FOR ACE INHIBITORS, 2004-2011 ($ MILLIONS)

Table 12 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, THROUGH 2011 ($ MILLIONS)

Figure 3 GLOBAL MARKET FOR ANGIOTENSIN II INHIBITORS, 2004-2011 ($ MILLIONS)

Table 13 SELECTED BETA BLOCKERS: PRECAUTIONS AND SIDE EFFECTS

Table 14 GLOBAL MARKET FOR BETA BLOCKERS, THROUGH 2011 ($ MILLIONS)

Figure 4 GLOBAL MARKET FOR BETA BLOCKERS, 2004-2011 ($ MILLIONS)

Table 15 SELECTED CALCIUM CHANNEL BLOCKERS: PRECAUTIONS AND SIDE EFFECTS

Table 15 (CONTINUED)

Table 16 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, THROUGH 2011 ($ MILLIONS)

Figure 5 GLOBAL MARKET FOR CALCIUM CHANNEL BLOCKERS, 2004-2011 ($ MILLIONS)

Table 17 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, THROUGH 2011 ($ MILLIONS)

Figure 6 GLOBAL MARKET FOR COMBINATION ANTIHYPERTENSIVE DRUGS, 2004-2011 ($ MILLIONS)

Table 18 GLOBAL MARKET FOR SELECTED PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 19 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, THROUGH 2011 ($ MILLIONS)

Figure 7 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT HYPERTENSION, 2004-2011 ($ MILLIONS)

Table 20 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERTENSION

Table 21 CURRENTLY AVAILABLE ASSISTED REPRODUCTIVE TECHNOLOGIES

Table 21 (CONTINUED)

Table 22 U.S. ASSISTED REPRODUCTIVE TECHNOLOGY PROCEDURE VOLUMES, THROUGH 2011

Table 22 (CONTINUED)

Table 23 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, 1998

Table 24 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, NONDONER EGGS, 2003

Table 25 U.S. PREGNANCY SUCCESS RATES FOR ART PROCEDURES, DONOR EGGS, 2003

Table 26 EFFECT OF PREVIOUS UNSUCCESSFUL IVF ATTEMPTS ON LIVE BIRTH RATE PER CYCLE

Table 27 EFFECT OF AGE OF WOMAN ON IVF LIVE BIRTH RATE PER CYCLE

Table 28 EFFECT OF CAUSE OF IVF INFERTILITY ON LIVE BIRTH RATE PER CYCLE

Table 29 U.S. IN VITRO FERTILIZATION PROCEDURE VOLUMES, THROUGH 2006

Table 30 U.S. GAMETE INTRAFALLOPIAN TRANSFER AND ZYGOTE INTRAFALLOPIAN TRANSFER PROCEDURE VOLUMES, THROUGH 2006

Table 31 U.S. MARKET FOR INFERTILITY TREATMENT, THROUGH 2011 ($ MILLIONS)

Table 32 U.S. COSTS OF INFERTILITY DIAGNOSTICS AND TREATMENTS, 2005 ($)

Table 33 SELECTED PHARMACEUTICAL AGENTS FOR THE TREATMENT OF FEMALE INFERTILITY

Table 33 (CONTINUED)

Table 34 MANUFACTURERS OF FERTILITY DRUGS AND THEIR PRODUCTS

Table 34 (CONTINUED)

Table 35 LEADING FERTILITY DRUGS BY INDICATION

Table 36 GONADOTROPIN USAGE IN SELECTED COUNTRIES (ESTIMATED NUMBER OF AMPOULES PER 1,000 INHABITANTS)

Table 37 GLOBAL SALES OF SELECTED FERTILITY DRUGS, THROUGH 2011

Table 38 GEOGRAPHIC SHARES OF INFERTILITY PHARMACEUTICALS, THROUGH 2011 ($ MILLIONS)

Figure 8 INFERTILITY DRUGS: GLOBAL SUPPLIER MARKET SHARES, 2005 (PERCENT)

Table 39 FERTILITY DRUGS IN PHASE II OR LATER DEVELOPMENT

Table 40 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERTHYRODISM, THROUGH 2011 ($ MILLIONS)

Table 41 DRUGS USED TO TREAT HYPOTHYROIDISM

Table 42 GLOBAL SALES OF SELECTED DRUGS TO TREAT HYPOTHYROIDISM, THROUGH 2011

Table 43 CLASSES OF LIPID-LOWERING DRUGS

Table 43 (CONTINUED)

Table 44 STATIN DRUGS AVAILABLE GLOBALLY AND THEIR GENERIC AVAILABILITY IN THE U.S.

Table 45 ANTIHYPERLIPIDEMIC DRUGS ON THE MARKET

Table 45 (CONTINUED)

Table 46 GLOBAL MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 47 U.S. MARKET FOR PRODUCTS TO TREAT HYPERCHOLESTEROLEMIA, THROUGH 2011 ($ MILLIONS)

Table 48 SELECTED DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS

Table 49 GLOBAL MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY BY PRODUCT, THROUGH 2011 ($ MILLIONS)

Table 50 U.S. MARKET FOR PRESCRIPTION PRODUCTS TO TREAT OBESITY, THROUGH 2011 ($ MILLIONS)

Table 51 DRUGS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF OBESITY

Table 52 ARENA PHARMACEUTICALS DRUG-DEVELOPMENT PIPELINE